Natalia Bednarz-Knoll1, Marta Popęda2, Tomasz Kryczka3,4, Barbara Kozakiewicz5,6, Katarzyna Pogoda7, Jolanta Szade8, Aleksandra Markiewicz2, Damian Strzemecki4,9, Leszek Kalinowski10,11, Jarosław Skokowski12, Jian Liu13, Anna J Żaczek14. 1. Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland. nbk@gumed.edu.pl. 2. Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland. 3. Department of Development of Nursing and Social and Medical Sciences, Medical University of Warsaw, Warsaw, Poland. 4. Department of Experimental Pharmacology, Medical Research Centre of Polish Academy of Science, Warsaw, Poland. 5. Oncological Prevention Department, Medical University of Warsaw, Warsaw, Poland. 6. Radiotherapy Unit, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 7. Department of Breast Cancer and Reconstructive Surgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 8. Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland. 9. Department of Immunology, Medical University of Warsaw, Warsaw, Poland. 10. Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdańsk, Gdańsk, Poland. 11. BioTechMed Centre, Department of Mechanics of Materials and Structures, University of Technology, Gdańsk, Poland. 12. Department of Surgical Oncology, Medical University of Gdańsk, Gdańsk, Poland. 13. Institute of Functional Nano and Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, China. 14. Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland. azaczek@gumed.edu.pl.
Abstract
BACKGROUND: Platelets support tumour progression. However, their prognostic significance and relation to circulating tumour cells (CTCs) in operable breast cancer (BrCa) are still scarcely known and, thus, merit further investigation. METHODS: Preoperative platelet counts (PCs) were compared with clinical data, CTCs, 65 serum cytokines and 770 immune-related transcripts obtained using the NanoString technology. RESULTS: High normal PC (hPC; defined by the 75th centile cut-off) correlated with an increased number of lymph node metastases and mesenchymal CTCs in the 70 operable BrCa patients. Patients with hPC and CTC presence revealed the shortest overall survival compared to those with no CTC/any PC or even CTC/normal PC. Adverse prognostic impact of hPC was observed only in the luminal subtype, when 247 BrCa patients were analysed. hPC correlated with high content of intratumoural stroma, specifically its phenotype related to CD8+ T and resting mast cells, and an increased concentration of cytokines related to platelet activation or even production in bone marrow (i.e. APRIL, ENA78/CXCL5, HGF, IL16, IL17a, MDC/CCL22, MCP3, MMP1 and SCF). CONCLUSIONS: Preoperative platelets evaluated alone and in combination with CTCs have prognostic potential in non-metastatic BrCa and define patients at the highest risk of disease progression, putatively benefiting from anti-platelet therapy.
BACKGROUND: Platelets support tumour progression. However, their prognostic significance and relation to circulating tumour cells (CTCs) in operable breast cancer (BrCa) are still scarcely known and, thus, merit further investigation. METHODS: Preoperative platelet counts (PCs) were compared with clinical data, CTCs, 65 serum cytokines and 770 immune-related transcripts obtained using the NanoString technology. RESULTS: High normal PC (hPC; defined by the 75th centile cut-off) correlated with an increased number of lymph node metastases and mesenchymal CTCs in the 70 operable BrCa patients. Patients with hPC and CTC presence revealed the shortest overall survival compared to those with no CTC/any PC or even CTC/normal PC. Adverse prognostic impact of hPC was observed only in the luminal subtype, when 247 BrCa patients were analysed. hPC correlated with high content of intratumoural stroma, specifically its phenotype related to CD8+ T and resting mast cells, and an increased concentration of cytokines related to platelet activation or even production in bone marrow (i.e. APRIL, ENA78/CXCL5, HGF, IL16, IL17a, MDC/CCL22, MCP3, MMP1 and SCF). CONCLUSIONS: Preoperative platelets evaluated alone and in combination with CTCs have prognostic potential in non-metastatic BrCa and define patients at the highest risk of disease progression, putatively benefiting from anti-platelet therapy.
Authors: S Krenn-Pilko; U Langsenlehner; E-M Thurner; T Stojakovic; M Pichler; A Gerger; K S Kapp; T Langsenlehner Journal: Br J Cancer Date: 2014-03-27 Impact factor: 7.640
Authors: Cor J Ravensbergen; Matthew Kuruc; Meaghan Polack; Stijn Crobach; Hein Putter; Hans Gelderblom; Devjit Roy; Rob A E M Tollenaar; Wilma E Mesker Journal: Cancers (Basel) Date: 2021-12-29 Impact factor: 6.639